通过抑制ERAD诱导的蛋白静态崩,FOSL2驱动急性骨髓性白血病发生

Wangshi Li1, Meiling Sun1, Binyu Yao1

  • 1Department of Critical Care Medicine, Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China; NHC Key Laboratory of Cell Transplantation, Key Laboratory of Hepatosplenic Surgery of Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, China.

概括

FOSL2驱动急性髓性白血病 (AML) 的生存率和化学抵抗. 针对FOSL2及其相关的ERAD通路提供了一种新的治疗策略,以改善AML患者的治疗结果.